Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $1.35B |
| Gross Profit (TTM) | $802.16M |
| EBITDA | $358.79M |
| Operating Margin | 17.90% |
| Return on Equity | 11.20% |
| Return on Assets | 6.60% |
| Revenue/Share (TTM) | $29.08 |
| Book Value | $18.41 |
| Price-to-Book | 5.81 |
| Price-to-Sales (TTM) | 3.98 |
| EV/Revenue | 4.298 |
| EV/EBITDA | 9.36 |
| Quarterly Earnings Growth (YoY) | 2.90% |
| Quarterly Revenue Growth (YoY) | 5.60% |
| Shares Outstanding | $45.50M |
| Float | $44.89M |
| % Insiders | 1.26% |
| % Institutions | 112.56% |
Volatility is currently expanding
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the Australian biotechnology company, expects to finish rolling out Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of 2027.
CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HAE and any ticker you trade — then tracks every position and per-strategy win rate.
